Key Takeaways
JD Health (06618.HK) shares fell more than 5 percent after Nomura cut its price target to HKD67, citing a decline in non-operating income.
"A decline in non-operating income weighed on net profit," Nomura said in a research report, while noting the company's pharmaceutical sales and operating profit remained strong.
The brokerage lowered its target to HKD67 from a previous HKD80 but maintained a "Buy" rating on the stock. Based on the last closing price of HKD45.74, the new target implies a 46.5 percent upside. The stock hit an intraday low of HKD45.68 on turnover of HKD275 million.
The significant price drop despite the maintained "Buy" rating shows investor concern over profitability drivers outside of core operations. The focus now shifts to how the company addresses its non-operating income streams in future earnings reports.
The drop in JD Health's stock occurred while broader Asian markets closed in the green. China’s Shanghai Composite Index ended Wednesday up 0.67 percent and Japan’s Nikkei 225 closed 0.84 percent higher, with both markets lifted by gains in technology stocks.
The target price cut from a major institution like Nomura could trigger further analysis from other firms and lead to sustained pressure on the stock. Investors will be watching for commentary from management on non-operating income in the next earnings release.
This article is for informational purposes only and does not constitute investment advice.
